STOP PKD

SGLT2 inhibition for the treatment of polycystic kidney disease

About the project What's ADPKD?

What is STOP PKD about?

The STOP-PKD study is investigating a new treatment option for people with autosomal dominant polycystic kidney disease (ADPKD). The study aims to determine whether an already approved medication from the class of so-called SGLT2 inhibitors (dapagliflozin) can have a positive effect on the course of ADPKD.

What is ADPKD?

ADPKD is a hereditary condition characterised by the formation of numerous small cysts (fluid-filled sacs) in the kidneys. Over time, these cysts grow, causing the kidneys to gradually lose their function. Those affected often require dialysis or a kidney transplant by middle age.

News

LMU Munich- Start of a new trial site

on Apr 13, 2026 at 08:45 AM

LMU Munich- Start of a new trial site

Groningen- Start of the 1st Dutch trial site

on Apr 08, 2026 at 08:18 AM

Groningen- Start of the 1st Dutch trial site

Lübeck - Start of a new trial site

on Apr 02, 2026 at 12:23 PM

Lübeck - Start of a new trial site

Jena- Start of a new trial site

on Apr 02, 2026 at 11:20 AM

Jena- Start of a new trial site

Hannover- Start of a new trial site

on Apr 02, 2026 at 11:18 AM

Hannover- Start of a new trial site

Berlin - Start of a new trial site

on Apr 02, 2026 at 10:17 AM

Berlin - Start of a new trial site

Aachen - Start of a new trial site

on Apr 02, 2026 at 10:16 AM

Aachen - Start of a new trial site

Frankfurt - Start of a new trial site

on Apr 02, 2026 at 10:15 AM

Frankfurt - Start of a new trial site

Mainz - Start of second trial site

on Feb 24, 2026 at 02:14 AM

Mainz - Start of second trial site